Proteomics and biomarkers in clinical trials for drug development
about
Confronting the Care Delivery Challenges Arising from Precision MedicineA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesFeasibility and safety of sequential research-related tumor core biopsies in clinical trials.Biobank resources for future patient care: developments, principles and concepts.PeptideManager: a peptide selection tool for targeted proteomic studies involving mixed samples from different species.Internal standard strategies for relative and absolute quantitation of peptides in biological matrices by liquid chromatography tandem mass spectrometry.Safety and diagnostic accuracy of tumor biopsies in children with cancer.Enrichment of phosphorylated peptides and proteins by selective precipitation methods.Microvesicles/exosomes as potential novel biomarkers of metabolic diseasesMeeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.Personalized oncology in interventional radiology.Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel.Application of proteomics in the study of rodent models of cancer.Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.Development of immunoassays using interferometric real-time registration of their kinetics.Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture.An osmolyte-based micro-volume ultrafiltration technique.Detection of protein complexes using a protein ranking algorithm.The crucial role of multiomic approach in cancer research and clinically relevant outcomes.Nanomaterials engineering for drug delivery: a hybridization approach
P2860
Q26747282-4D6E998C-A66D-49DC-AEAC-DE760B039C72Q26786354-BFDA6AB9-2F81-4614-A038-1C93ECBDBC53Q33162197-15CFEDF9-6506-4FB2-AA99-83378931C4C8Q34020952-3B9F6784-9001-458C-9E5B-0C0F5C9AD8B8Q34117442-28169E30-F86C-41B4-8A67-F97D201B6533Q34310103-4E4A4ACF-06AE-42D3-B991-97269EFEB760Q35202350-9CF80CFC-DEBB-46F2-83D2-541521B078E1Q35542665-9431799F-B731-4C13-ABE3-FD0A9F93EB4BQ36175435-D6A88D80-B164-439E-9924-A21FD7260EBAQ36358324-C3666A98-2463-4304-8246-28D2E25EDEE0Q36910794-004F2E14-065B-4300-B215-AFA75FE5CD0BQ37092371-7CFA9159-374B-4D0A-84AB-5F0292DD0036Q37324763-0F96B3D2-97BA-4BAB-939F-5B42CCEE93A4Q38194543-C165DBBB-C166-487D-B15B-326173AF9393Q38228652-975A9CB4-E5DB-4314-BE42-E4B4BBC75C81Q38765422-28488F8B-65F4-4C45-97E5-11AA8F834732Q38962751-DF541FDF-240C-4F03-B665-CE6536411FC5Q39468169-DC365390-0684-4AA2-9B53-DCBD2A9599A8Q46829465-B59BCB37-0F61-4235-BDA6-18BCE7DF4B9FQ51356483-F6D89B00-F4F5-493F-B2BF-553C10A5179FQ52363678-7BEF892D-0501-4803-AB4F-B826F3192BEDQ57367599-BFFEEB66-98B8-4781-A699-EAF41B690B0B
P2860
Proteomics and biomarkers in clinical trials for drug development
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Proteomics and biomarkers in clinical trials for drug development
@ast
Proteomics and biomarkers in clinical trials for drug development
@en
type
label
Proteomics and biomarkers in clinical trials for drug development
@ast
Proteomics and biomarkers in clinical trials for drug development
@en
prefLabel
Proteomics and biomarkers in clinical trials for drug development
@ast
Proteomics and biomarkers in clinical trials for drug development
@en
P2093
P2860
P1476
Proteomics and biomarkers in clinical trials for drug development
@en
P2093
Elise C Kohn
Gary Altwerger
Jasmine J Han
Jung-min Lee
P2860
P304
P356
10.1016/J.JPROT.2011.04.023
P577
2011-05-04T00:00:00Z